An objective comparison of continuous 365-day digital partnering engines, event-driven networking, and enterprise deal rooms for human and animal health business development.
| Feature / Metric | 1IBHub | BePharma / PharmaVenue | b2match / Health.tech | IN-PART | Pipelinepharma | Allan Lloyds (Global Medical Affairs Summit) | euroPLX (RauCon) | CPhI (Informa Markets / cphi.com) | PharmaVentures |
|---|---|---|---|---|---|---|---|---|---|
| Pricing model | Flat €299 / year | €1,500 – €5,000+ per event ticket | Event ticket + platform add-ons | $10,000 – $50,000+ enterprise annual | Free basic / project & success fees | €3,500 per delegate ticket (2-day physical event) | €1,100 – €1,700 per delegate per event (+ travel & hotel) | €499 – €3,999 per pass (€15,000 – €70,000+ for exhibitors incl. travel/stand) | Advisory retainers + transaction success commissions |
| Brokerage / success fees | 0% brokerage fees | 0% (event cost only) | 0% (event cost only) | 0% (SaaS enterprise fee) | Success & project commission fees | 0% (high ticket event cost only) | 0% (event registration fees only) | 0% (high exhibition & registration cost) | Success commissions & percentage cuts on completed transactions |
| Availability window | Continuous 365-day access | 2–3 day event sprints | 2–3 day conference sprints | 365-day deal room | 365-day directory & services | 2-day annual physical event (Berlin) | Periodic 2-day meetings (3–4 times per year) + limited video windows | 3-day annual mega-exhibition + short pre-show app access | Project-based advisory mandates (6–12 month cycles) |
| Taxonomy precision | Full WHO ATC (1–5) & EPHMRA 2026 NFC (1–3) | Generic keyword search | General therapeutic tags | Early-stage R&D keywords | Basic dosage / active form tags | None (broad agenda topics: Medical Affairs, RWE, HEOR, GenAI) | Basic general category dropdowns (Rx, OTC, Generics, Medical Devices) | Broad industry tags (APIs, FDF, CDMO, Machinery) | None (manual target research & advisory screening) |
| IP privacy & anonymity | Blind Profiles (double opt-in reveal) | Public registration list | Open participant directory | Non-confidential summaries | Direct company listing | Public attendee directory & speed networking | Pre-scheduled meeting directory & delegate list | Public exhibitor directory & attendee list | Manual non-confidential teasers (NCDs) distributed by advisors |
| Market focus | Commercial assets (Generics, Biosimilars, VAPs, Rx/OTC) & CDMO/CRO services | LatAm & EU generic / VAP commercial assets | Regional digital health & medtech clusters | Early-stage university tech transfer & Big Pharma R&D | Commercial generics, dossiers & distribution deals | High-level Medical Affairs strategy, MSL leadership, RWE & scientific communications | Commercial licensing, Generics, VAPs, OTC/Rx assets & CDMO/supply deals | Global pharmaceutical supply chain, APIs, finished dosage licensing, CDMO/CRO | High-ticket M&A, divestments, early-to-commercial licensing and valuations |
| Dual-sector coverage | Human & Animal Health | Human Health primarily | Human Health & Tech | Human Health & Biotech | Human Health primarily | Human Health primarily (large-cap & mid-sized pharma) | Human Health primarily | Human Health primarily (with broad veterinary supply) | Human Health & Life Sciences (Biotech, Pharma, CDMO/CRO) |
Third-party information reflects publicly available indications as of September 2026 and may vary by event, package or region. Please verify current terms with each provider. All trademarks belong to their respective owners.
bepharma.org · pharmavenue.com
Event-driven partnering for generic and value-added commercial assets, strongest in Latin America and Europe. Value is concentrated in a short event window, with ticket costs per attendee.
Best if you want in-person meetings at a specific regional event.
b2match.com · health.tech
Meeting-scheduling platforms attached to conferences and regional clusters, typically with open participant directories and broad therapeutic tags.
Best for conference attendees in digital health and medtech.
inpart.io
Enterprise-priced deal room connecting universities and R&D teams around early-stage technologies via non-confidential summaries.
Best for early-stage academic tech-transfer scouting with an enterprise budget.
pipelinepharma.com
Directory and marketplace for commercial generics, dossiers and distribution, with project and success-based fees on transactions.
Best if you prefer a free entry tier and accept success fees.
mdaffairs.com
A 2-day annual physical congress in Berlin for Medical Affairs leadership, MSL teams, RWE/HEOR and scientific communications, with an agenda-led programme, a public attendee directory and speed networking. Deal sourcing is not structured around asset-level criteria — the value sits in a single high-ticket networking window each year.
Best for Medical Affairs executives seeking in-person strategy networking in Berlin, not for asset-level deal sourcing.
europlx.com
Periodic 2-day partnering meetings held three to four times per year, built around pre-scheduled bilateral meetings with a delegate directory and limited video windows. Classification relies on basic general category dropdowns (Rx, OTC, Generics, Medical Devices), with per-event delegate fees plus travel and hotel costs.
Best for commercial licensing teams who prefer recurring in-person meeting rounds on a fixed event calendar.
cphi.com
The global pharmaceutical supply-chain mega-exhibition: three days each year plus a short pre-show app window, with broad industry tags (APIs, FDF, CDMO, Machinery), public exhibitor and attendee directories, and per-pass fees ranging from €499 to €3,999 — with exhibiting companies paying €15,000–€70,000+ once travel and stand costs are included. Coverage spans APIs, finished dosage licensing and CDMO/CRO, but access is concentrated in a single annual window with no asset-level taxonomy.
Best for supply-chain and sourcing teams who plan an annual exhibition visit.
pharmaventures.com
A specialist advisory firm for high-ticket M&A, divestments, early-to-commercial licensing and valuations, working on project mandates that typically run 6–12 months. Deal flow is screened manually rather than via taxonomy, and counterparties are approached with advisor-distributed non-confidential teasers (NCDs). Compensation comes from retainers plus success commissions — commonly 3–5%+ of deal value.
Best for large transactions where a retained advisor and percentage-based success fee fit the deal size.
1ibhub.com
A continuous 365-day digital partnering engine for products and services across human and animal health. Blind Profiles protect identity until double opt-in; full WHO ATC 1–5 and EPHMRA NFC 1–3 filters isolate exact fits; flat €299/year with zero brokerage fees.
Best for BD teams sourcing or out-licensing commercial assets and services year-round.
Flat €299 per year, zero brokerage fees, Blind Profiles and full ATC/NFC precision.
Join 1IBHub